Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and counterproductive. This report presents the case of a 77-year-old Caucasian male with extensive-stage refractory SCLC who was restarted on platinum doublets as part of a clinical trial called TRIPLE THREAT (NCT02489903) involving pretreatment with the epi-immunotherapeutic agent RRx-001, and who achieved a partial response after only 4 cycles. The patient had received a platinum drug twice before, in 2009 for a diagnosis of non-small-cell lung cancer (squamous cell carcinoma) and in 2015 for SCLC, sugg...
We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mu...
BackgroundSmall cell lung cancer (SCLC) is the most aggressive lung tumor, characterized by a rapid ...
Introduction Patients with small-cell lung cancer (SCLC) that progresses after first-line (FL) chemo...
Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, in...
As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration...
As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration...
RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced ...
RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced ...
RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the r...
RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the r...
BACKGROUND: This exploratory single-arm phase II study evaluated the efficacy and safety of RRx-001 ...
This case report describes the clinical course of a heavily pretreated patient enrolled on the Phase...
Few therapeutic options are available for T790M-negative non-small cell lung cancer (NSCLC) after fa...
Small-cell lung cancer has a high chemotherapeutic sensitivity but with disappointing outcome result...
We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for p...
We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mu...
BackgroundSmall cell lung cancer (SCLC) is the most aggressive lung tumor, characterized by a rapid ...
Introduction Patients with small-cell lung cancer (SCLC) that progresses after first-line (FL) chemo...
Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, in...
As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration...
As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration...
RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced ...
RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced ...
RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the r...
RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the r...
BACKGROUND: This exploratory single-arm phase II study evaluated the efficacy and safety of RRx-001 ...
This case report describes the clinical course of a heavily pretreated patient enrolled on the Phase...
Few therapeutic options are available for T790M-negative non-small cell lung cancer (NSCLC) after fa...
Small-cell lung cancer has a high chemotherapeutic sensitivity but with disappointing outcome result...
We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for p...
We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mu...
BackgroundSmall cell lung cancer (SCLC) is the most aggressive lung tumor, characterized by a rapid ...
Introduction Patients with small-cell lung cancer (SCLC) that progresses after first-line (FL) chemo...